Mateo, FrancescaLópez Bigas, NúriaPujana, Miguel Angel2017-07-042017-07-042017Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, Ruiz de Garibay G, Boni J, Maicas M et al. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017; 36: 2737-2749. DOI: 10.1038/onc.2016.4270950-9232http://hdl.handle.net/10230/32499Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.application/pdfeng© Nature Publishing Group. http://dx.doi.org/10.1038/onc.2016.427. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1038/onc.2016.427info:eu-repo/semantics/openAccess